WO2012007113A1 - Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough - Google Patents

Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough Download PDF

Info

Publication number
WO2012007113A1
WO2012007113A1 PCT/EP2011/003284 EP2011003284W WO2012007113A1 WO 2012007113 A1 WO2012007113 A1 WO 2012007113A1 EP 2011003284 W EP2011003284 W EP 2011003284W WO 2012007113 A1 WO2012007113 A1 WO 2012007113A1
Authority
WO
WIPO (PCT)
Prior art keywords
dry cough
tamarind
seeds
preparation
polysaccharide
Prior art date
Application number
PCT/EP2011/003284
Other languages
French (fr)
Inventor
Elsa Melloni
Marco Sardina
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Priority to ES11745921.4T priority Critical patent/ES2560954T3/en
Priority to CN201180004954.4A priority patent/CN102686232B/en
Priority to SI201130726T priority patent/SI2593119T1/en
Priority to EP11745921.4A priority patent/EP2593119B1/en
Priority to MX2012005818A priority patent/MX2012005818A/en
Priority to BR112012011818-8A priority patent/BR112012011818B1/en
Priority to EA201270563A priority patent/EA023654B1/en
Priority to PL11745921T priority patent/PL2593119T3/en
Priority to RS20160055A priority patent/RS54637B1/en
Publication of WO2012007113A1 publication Critical patent/WO2012007113A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/14Antitussive agents

Definitions

  • the present invention relates to the use of polysaccharide polymer obtained from the seeds of the tamarind tree for treating dry cough.
  • the present invention relates to treatment of the dry cough in children.
  • Dry cough often occurs at the end of viral infections affecting the upper respiratory airways such as a cold and flu, or after the exposure to a variety of irritating factors including allergens, dust, smoke, cleaning agents, chemical air pollutants and contaminants, prolonged stay in dry environments and physical traumas.
  • Dry cough typically does not last longer than 2-3 weeks.
  • a person suffering from dry cough experiences an unpleasant feeling of burning and dryness of the high respiratory airways and an uncomfortable tickling in the throat, which usually begins the attacks of cough.
  • dry cough is mild throughout the day and often gets more intense at night, preventing a person from sleeping or resting. Sometimes dry cough occurs only at night, after the person goes to sleep.
  • Dry cough is very common in children. Children who cough during the night may have problems to sleep, and such problems may involve also their parents
  • Traditional homemade remedies include, for example, fresh ginger, saline solution and honey.
  • Tamarind tree is widespread in India, Africa and in the South East Asia.
  • tamarind juice from the tamarind fruit can be a drink prepared by infusing dried tamarind pulp.
  • Tamarind can also be useful for the preservation of food products and as a sauce in recipes.
  • the tamarind seed finds various applications, once ground to the powder form (known as "tamarind gum” or “tamarind kernel powder”).
  • tamarind kernel powder can be employed as thickener and a sizing agent in textile and paper industries; and as thickening, gelling, stabilizing and binding agent in food and pharmaceutical industries.
  • a polysaccharide polymer obtained from the seeds of the tamarind tree provides dry cough relief and maintains the relief for an extended period of time that is long enough to allow, for example, the adults and children to fall asleep and enjoy a satisfactory sleep time.
  • Tamarind seed polysaccharide is a nonionic, neutral, branched polysaccharide comprising a cellulose-like backbone substituted by xylose (a 1 ⁇ 6) and galacto ( ⁇ l ⁇ 2)xylose (a 1 ⁇ 6) substituents (Lang P. et al., Macromolecules, 1993, 26, 3992- 3998).
  • Tamarind seed polysaccharide suitable for the preparations according to the present invention may be obtained according to any method known in the art, preferably following the methods described in WO 97/28787.
  • Tamarind seed polysaccharide according to the invention is particularly effective for treating dry cough in children, especially at night, when cough is particularly bothersome because it disrupts sleep.
  • a polysaccharide polymer obtained from the seeds of the tamarind tree according to the invention is locally administered to the mucous membranes of the high respiratory airways of a subject suffering from dry cough as an aerosolized liquid preparation, by suitable commercially available inhalation devices.
  • the preparation according the invention contains from 0.25 to 0.5 w/v% (hereunder the unit “w/v%” is referred to as "%" for simplicity) of the polysaccharide polymer obtained from the seeds of the tamarind tree.
  • the preparation according the invention contains 0.3% of the polysaccharide polymer obtained from the seeds of the tamarind tree.
  • the preparation according to the invention can further comprise pH adjusting agents well known to a person skilled in the art, including pharmaceutically acceptable acids or bases and buffering agents.
  • the acids may include one or more inorganic mineral acids such as hydrochloric, hydrobromic, sulfuric, phosphoric and nitric acid, or one or more organic acids such as acetic, succinic, tartaric, ascorbic, citric, glutamic, benzoic, methanesulphonic, ethanesulfonic and trifluoroacetic acid.
  • the bases may include inorganic bases and organic bases, such as alkaline carbonate, alkaline bicarbonate, alkaline earth metal carbonate, alkaline hydroxide and alkaline - 4 - earth metal hydroxide.
  • the inorganic base may be an alkaline hydroxide such as lithium hydroxide, potassium hydroxide, cesium hydroxide or sodium hydroxide; an alkaline carbonate may be calcium carbonate or sodium carbonate; an alkaline bicarbonate may be sodium bicarbonate.
  • buffering agents include a phosphate buffer such as sodium dihydrogen phosphate commonly termed monosodium phosphate (NaH ⁇ PC ⁇ ) and disodium hydrogen phosphate commonly termed disodium phosphate (Na 2 HP0 4 ), an acetate buffer (sodium acetate-acetic acid system) a citrate buffer (sodium citrate-citric acid system) and mixtures thereof.
  • the buffering agent is preferably selected from monosodium phosphate (NaH 2 P0 ), disodium phosphate (Na 2 HP0 ) or mixture thereof, and sodium citrate-citric acid system.
  • the type and concentration of the pH adjusting agents suitable for use in the disclosed preparation would be dependent on the desired pH value which ranges within 6.0 to 8.0, preferably within 6.8 and 7.5.
  • the isotonicity of the preparation vehicle is preferably adjusted by sodium chloride.
  • the local administration to the mucous membranes of the high respiratory airways of a subject suffering from dry cough of the preparation according to the invention is carried out by an aerosol delivery system; the aerosolized liquid preparation is therefore sufficiently mobile to coat a wide area of the mucosal surface of the upper respiratory tract, thus providing effective relief of dry cough.
  • the aerosol delivery system is a commercially available nebulizer, such as a jet nebulizer, which accepts the liquid preparation and transforms said liquid preparation into fine droplets, so that it can be easily inhaled through a mouthpiece or a face mask.
  • a jet nebulizer such as a jet nebulizer
  • a jet of air is forced through the preparation according to the invention, turning it into fine droplets which are moved along a tube.
  • the subject inhales the preparation, through a mouthpiece or a face mask.
  • a face mask is preferably used for pediatric subjects.
  • the preparation according to the invention can be administered to a subject suffering from dry cough on as-needed or as-desired basis, for example, at least once daily and P2011/003284
  • - 5 - preferably multiple, for example 2 or 3 times daily.
  • the amount of the preparation administered to a subject may be dependent on a variety of factors, including the general quality of health of the subject, age, gender, weight, or severity of dry cough. For example, from 6 to 18 mg/day of tamarind seed polysaccharide can be administered to a subject in need thereof.
  • a process for preparing a preparation as described above can be carried out according to methods well known to a person skilled in the art; for example, said process comprises dissolving the tamarind seed polysaccharide in purified water such as water for injections and adding a pH adjusting agent until the desired pH is reached.
  • a polysaccharide polymer obtained from the seeds of the tamarind tree includes mixtures of polysaccharide polymers obtained from the seeds of the tamarind tree.
  • high respiratory tract includes nasal, sinus, pharyngeal, laryngeal, tracheal, and bronchial compartments.
  • inhalation or “administration by inhalation” refers to the introduction into the respiratory organs, especially into and/or via the airways, preferably into and/or via the nasal cavity and oral cavity.
  • nebulizer includes jet nebulizers.
  • polysaccharide polymer obtained from the seeds of the tamarind tree interchangeable with the term “tamarind seed polysaccharide” and abbreviated as "TSP" means any polysaccharide-enriched fraction obtainable from tamarind kernel powder currently available on the market.
  • a partially purified polysaccharide fraction of tamarind gum is sold, for instance, by Dainippon Pharmaceutical Co. LTD of Osaka, Japan, under the trade name Glyloid ® .
  • the concerned polysaccharide is preferably obtained following any method known in the art to give a practically pure tamarind seed polysaccharide from commercial tamarind gum sources.
  • preparation is intended in a broader sense to include not only all conventional pharmaceutical preparations but also preparations useful as diet supplements, medical devices and food additives.
  • the term "subject” refers to a human adult or a child afflicted with a dry cough.
  • treating means relieving, suppressing, reducing, decreasing, delaying, ameliorating, calming or preventing onset, progression, severity, duration, frequency of dry cough and not necessarily indicates a total elimination the same.
  • Example 1 illustrates some preparations according to the invention.
  • TSP tamarind seed polysaccharide
  • Example 2 illustrates the use in one adult subject of the first preparation of Example 1.
  • Example 1 One subject with cough following inflammation of the upper airways was selected to test the preparation of Example 1.
  • the preparation was locally administered by aerosol inhalation carried out by the nebulizer Fluirespira Professional (Zambon).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Use of a polysaccharide polymer obtained from the seeds of the tamarind tree for treating dry cough; said polysaccharide being locally administered to the mucous membranes of the high respiratory airways of a subject suffering from dry cough as an aerosolized liquid preparation, for example by suitable commercially available inhalation devices.

Description

POLYSACCHARIDE POLYMER FROM THE SEEDS OF THE TAMARIND TREE FOR USE IN TREAT DRY COUGH
*********************************
FIELD OF THE INVENTION
5 The present invention relates to the use of polysaccharide polymer obtained from the seeds of the tamarind tree for treating dry cough.
Especially, the present invention relates to treatment of the dry cough in children.
DESCRIPTION OF THE INVENTION
Dry cough often occurs at the end of viral infections affecting the upper respiratory airways such as a cold and flu, or after the exposure to a variety of irritating factors including allergens, dust, smoke, cleaning agents, chemical air pollutants and contaminants, prolonged stay in dry environments and physical traumas.
Dry cough typically does not last longer than 2-3 weeks.
Typically, a person suffering from dry cough experiences an unpleasant feeling of burning and dryness of the high respiratory airways and an uncomfortable tickling in the throat, which usually begins the attacks of cough.
In most cases, dry cough is mild throughout the day and often gets more intense at night, preventing a person from sleeping or resting. Sometimes dry cough occurs only at night, after the person goes to sleep.
Dry cough is very common in children. Children who cough during the night may have problems to sleep, and such problems may involve also their parents
Furthermore, if left untreated for a longer period of time, dry cough might complicate possibly resulting in chronic dry cough, or also in bacterial infections that complicate the clinical outcome, prolonging the time to recovery.
A lot of traditional homemade remedies and over-the-counter medicines are commonly used as first line treatment for dry cough.
Traditional homemade remedies include, for example, fresh ginger, saline solution and honey.
Common over-the-counter pharmacological remedies include, for example, dextromethorphan and diphenhydramine.
However, traditional homemade remedies, generally recognized as safe, are often T EP2011/003284
- 2 - ineffective in relieving the cough, whereas over-the-counter remedies are known to potentially cause side effects, such as allergic reactions, effects on sleep or hallucinations and they are not recommended for children, especially children under six years of age, because there is no clear evidence of their efficacy.
Thus, there is a need for an effective treatment of dry cough, without the adverse side-effects of the medicaments conventionally used for this purpose. The control of children cough during the night is particularly awaited, so achieving undisputed beneficial effect also on parental sleep.
Tamarind tree is widespread in India, Africa and in the South East Asia. In Middle Eastern countries, tamarind juice from the tamarind fruit can be a drink prepared by infusing dried tamarind pulp. Tamarind can also be useful for the preservation of food products and as a sauce in recipes.
The tamarind seed finds various applications, once ground to the powder form (known as "tamarind gum" or "tamarind kernel powder"). Commercially available tamarind kernel powder can be employed as thickener and a sizing agent in textile and paper industries; and as thickening, gelling, stabilizing and binding agent in food and pharmaceutical industries.
General properties, chemical composition and chemical structure of tamarind kernel powder and of tamarind seed polysaccharide can be found in: Gupta V, Puri R, Gupta S, Jain S, Rao GK.; Tamarind kernel gum: An upcoming natural polysaccharide. Syst Rev Pharm; 2010;1:50-4.
It has now surprisingly found that a polysaccharide polymer obtained from the seeds of the tamarind tree provides dry cough relief and maintains the relief for an extended period of time that is long enough to allow, for example, the adults and children to fall asleep and enjoy a satisfactory sleep time.
It is therefore a first object of the present invention a polysaccharide polymer obtained from the seeds of the tamarind tree (tamarind seed polysaccharide), for use in treating dry cough.
Tamarind seed polysaccharide is a nonionic, neutral, branched polysaccharide comprising a cellulose-like backbone substituted by xylose (a 1→6) and galacto (β l→2)xylose (a 1→6) substituents (Lang P. et al., Macromolecules, 1993, 26, 3992- 3998).
Tamarind seed polysaccharide suitable for the preparations according to the present invention may be obtained according to any method known in the art, preferably following the methods described in WO 97/28787.
Tamarind seed polysaccharide according to the invention is particularly effective for treating dry cough in children, especially at night, when cough is particularly bothersome because it disrupts sleep.
To achieve the desired effect, a polysaccharide polymer obtained from the seeds of the tamarind tree according to the invention is locally administered to the mucous membranes of the high respiratory airways of a subject suffering from dry cough as an aerosolized liquid preparation, by suitable commercially available inhalation devices.
It is therefore another object of the present invention a preparation in the form of a liquid dosage for aerosolized topical application, which comprises a polysaccharide polymer obtained from the seeds of the tamarind tree, said preparation being useful for treating dry cough, especially dry cough in children.
The preparation according the invention contains from 0.25 to 0.5 w/v% (hereunder the unit "w/v%" is referred to as "%" for simplicity) of the polysaccharide polymer obtained from the seeds of the tamarind tree. Preferably, the preparation according the invention contains 0.3% of the polysaccharide polymer obtained from the seeds of the tamarind tree.
The preparation according to the invention can further comprise pH adjusting agents well known to a person skilled in the art, including pharmaceutically acceptable acids or bases and buffering agents. For example, the acids may include one or more inorganic mineral acids such as hydrochloric, hydrobromic, sulfuric, phosphoric and nitric acid, or one or more organic acids such as acetic, succinic, tartaric, ascorbic, citric, glutamic, benzoic, methanesulphonic, ethanesulfonic and trifluoroacetic acid. The bases may include inorganic bases and organic bases, such as alkaline carbonate, alkaline bicarbonate, alkaline earth metal carbonate, alkaline hydroxide and alkaline - 4 - earth metal hydroxide. For example, the inorganic base may be an alkaline hydroxide such as lithium hydroxide, potassium hydroxide, cesium hydroxide or sodium hydroxide; an alkaline carbonate may be calcium carbonate or sodium carbonate; an alkaline bicarbonate may be sodium bicarbonate. For example, buffering agents include a phosphate buffer such as sodium dihydrogen phosphate commonly termed monosodium phosphate (NaH^PC^) and disodium hydrogen phosphate commonly termed disodium phosphate (Na2HP04), an acetate buffer (sodium acetate-acetic acid system) a citrate buffer (sodium citrate-citric acid system) and mixtures thereof. In a particular aspect of the present invention the buffering agent is preferably selected from monosodium phosphate (NaH2P0 ), disodium phosphate (Na2HP0 ) or mixture thereof, and sodium citrate-citric acid system.
The type and concentration of the pH adjusting agents suitable for use in the disclosed preparation would be dependent on the desired pH value which ranges within 6.0 to 8.0, preferably within 6.8 and 7.5.
The isotonicity of the preparation vehicle is preferably adjusted by sodium chloride. The local administration to the mucous membranes of the high respiratory airways of a subject suffering from dry cough of the preparation according to the invention is carried out by an aerosol delivery system; the aerosolized liquid preparation is therefore sufficiently mobile to coat a wide area of the mucosal surface of the upper respiratory tract, thus providing effective relief of dry cough.
Preferably, the aerosol delivery system is a commercially available nebulizer, such as a jet nebulizer, which accepts the liquid preparation and transforms said liquid preparation into fine droplets, so that it can be easily inhaled through a mouthpiece or a face mask.
As an example, when the jet nebulizer is turned on, a jet of air is forced through the preparation according to the invention, turning it into fine droplets which are moved along a tube. The subject inhales the preparation, through a mouthpiece or a face mask. A face mask is preferably used for pediatric subjects.
The preparation according to the invention can be administered to a subject suffering from dry cough on as-needed or as-desired basis, for example, at least once daily and P2011/003284
- 5 - preferably multiple, for example 2 or 3 times daily.
The amount of the preparation administered to a subject may be dependent on a variety of factors, including the general quality of health of the subject, age, gender, weight, or severity of dry cough. For example, from 6 to 18 mg/day of tamarind seed polysaccharide can be administered to a subject in need thereof.
A process for preparing a preparation as described above can be carried out according to methods well known to a person skilled in the art; for example, said process comprises dissolving the tamarind seed polysaccharide in purified water such as water for injections and adding a pH adjusting agent until the desired pH is reached.
As used herein, the singular forms "a," "an" and "the" include plural referents unless the context clearly states otherwise. Thus, for example, reference to "a polysaccharide polymer obtained from the seeds of the tamarind tree" includes mixtures of polysaccharide polymers obtained from the seeds of the tamarind tree. As used herein, the term "high respiratory tract" includes nasal, sinus, pharyngeal, laryngeal, tracheal, and bronchial compartments.
As used herein, the term "inhalation" or "administration by inhalation" refers to the introduction into the respiratory organs, especially into and/or via the airways, preferably into and/or via the nasal cavity and oral cavity.
As used herein, the term "nebulizer" includes jet nebulizers.
As used herein, the term "polysaccharide polymer obtained from the seeds of the tamarind tree", interchangeable with the term "tamarind seed polysaccharide" and abbreviated as "TSP", means any polysaccharide-enriched fraction obtainable from tamarind kernel powder currently available on the market. A partially purified polysaccharide fraction of tamarind gum is sold, for instance, by Dainippon Pharmaceutical Co. LTD of Osaka, Japan, under the trade name Glyloid®. For the purpose of the present invention, however, the concerned polysaccharide is preferably obtained following any method known in the art to give a practically pure tamarind seed polysaccharide from commercial tamarind gum sources.
As used herein, the term "preparation" is intended in a broader sense to include not only all conventional pharmaceutical preparations but also preparations useful as diet supplements, medical devices and food additives.
As used herein, the term "subject" refers to a human adult or a child afflicted with a dry cough.
As used herein the term "treating" means relieving, suppressing, reducing, decreasing, delaying, ameliorating, calming or preventing onset, progression, severity, duration, frequency of dry cough and not necessarily indicates a total elimination the same.
Example 1 illustrates some preparations according to the invention.
Example 1
The necessary amount of tamarind seed polysaccharide (TSP) was weighted into a suitable vessel, water for injection was added up to the final volume (100 percent) until complete dissolution of the TSP. The isotonicity of the preparation was adjusted by NaCl and pH adjusting agents were then added to maintain the pH within physiological pH (between 6.8 and 7.5). The so obtained preparation had the following composition:
TSP 0.3%
NaCl 0.9%,
Na2HP04 0.9%,
NaH2P04 0.09%
Water for injection to 100 ml
Following analogous procedure, the below preparation was obtained:
TSP 0.3%
NaCl 0.9%,
Citric acid 0.03%,
Sodium citrate 0.5%
Water for injection to 100 ml
Example 2 illustrates the use in one adult subject of the first preparation of Example 1. Example 2
One subject with cough following inflammation of the upper airways was selected to test the preparation of Example 1.
The preparation was locally administered by aerosol inhalation carried out by the nebulizer Fluirespira Professional (Zambon).
Application of the preparation was more effective than saline solution in alleviating the cough.
Furthermore the subject declared a pleasant hydrating and soothing sensation and relief of sensory discomfort in the upper airways.

Claims

1. Use of a polysaccharide polymer obtained from the seeds of the tamarind tree, for treating dry cough.
2. Use according to claim 1, wherein the polymer is locally administered to the mucous membranes of the high respiratory airways of a subject suffering from dry cough as an aerosolized liquid preparation.
3. Use according to claim 2, wherein the subject suffering from dry cough is a child.
4. A preparation in the form of a liquid dosage for aerosolized topical application, which comprises a polysaccharide polymer obtained from the seeds of the tamarind tree.
5. A preparation according to claim 4, which is locally administered to the mucous membranes of the high respiratory airways of a subject suffering from dry cough.
6. A preparation according to claim 5, wherein the polysaccharide is obtained by purification from commercial tamarind gum sources.
7. A preparation according to claim 5, which contains from 0.25 to 0.5% of the polysaccharide polymer obtained from the seeds of the tamarind tree.
8. A preparation according to claim 7, which contains 0.3% of the polysaccharide polymer obtained from the seeds of the tamarind tree.
9. A preparation according to claim 5, which further comprises a pH adjusting agent.
10. A preparation according to claim 9, wherein the pH adjusting agent is a buffering agent selected from monosodium phosphate (NaH2P04), disodium phosphate (Na2HP04), sodium citrate-citric acid system or mixture thereof.
PCT/EP2011/003284 2010-07-12 2011-07-01 Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough WO2012007113A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES11745921.4T ES2560954T3 (en) 2010-07-12 2011-07-01 Polysaccharide polymer of tamarind tree seeds for use in the treatment of dry cough
CN201180004954.4A CN102686232B (en) 2010-07-12 2011-07-01 Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough
SI201130726T SI2593119T1 (en) 2010-07-12 2011-07-01 Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough
EP11745921.4A EP2593119B1 (en) 2010-07-12 2011-07-01 Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough
MX2012005818A MX2012005818A (en) 2010-07-12 2011-07-01 Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough.
BR112012011818-8A BR112012011818B1 (en) 2010-07-12 2011-07-01 PREPARATION IN THE FORM OF A LIQUID DOSAGE FOR AEROSOLIZED TOPICAL APPLICATION
EA201270563A EA023654B1 (en) 2010-07-12 2011-07-01 Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough
PL11745921T PL2593119T3 (en) 2010-07-12 2011-07-01 Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough
RS20160055A RS54637B1 (en) 2010-07-12 2011-07-01 Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10007151.3 2010-07-12
EP10007151 2010-07-12

Publications (1)

Publication Number Publication Date
WO2012007113A1 true WO2012007113A1 (en) 2012-01-19

Family

ID=43410370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/003284 WO2012007113A1 (en) 2010-07-12 2011-07-01 Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough

Country Status (14)

Country Link
EP (1) EP2593119B1 (en)
CN (1) CN102686232B (en)
BR (1) BR112012011818B1 (en)
CO (1) CO6561774A2 (en)
EA (1) EA023654B1 (en)
ES (1) ES2560954T3 (en)
HU (1) HUE028534T2 (en)
MX (1) MX2012005818A (en)
MY (1) MY162322A (en)
PL (1) PL2593119T3 (en)
PT (1) PT2593119E (en)
RS (1) RS54637B1 (en)
SI (1) SI2593119T1 (en)
WO (1) WO2012007113A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013023856A1 (en) * 2011-08-12 2013-02-21 Zambon S.P.A. Use of a polysaccharide polymer from the seeds of the tamarind seed in protecting against tobacco-associated damages

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028787A1 (en) 1996-02-05 1997-08-14 Farmigea S.P.A. Ophthalmic solutions viscosified with tamarind seed polysaccharide
WO2004113390A1 (en) * 2003-06-20 2004-12-29 Noveon Ip Holdings Corp. Galactomannan hydrocolloids
WO2006069213A1 (en) * 2004-12-22 2006-06-29 Schering Corporation Pharmaceutical formulations
WO2009040847A2 (en) * 2007-08-13 2009-04-02 N.B.S. S.R.L. Dermocosmetic compositions based on tamarind seed polysaccharide and vegetable extracts

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028787A1 (en) 1996-02-05 1997-08-14 Farmigea S.P.A. Ophthalmic solutions viscosified with tamarind seed polysaccharide
WO2004113390A1 (en) * 2003-06-20 2004-12-29 Noveon Ip Holdings Corp. Galactomannan hydrocolloids
WO2006069213A1 (en) * 2004-12-22 2006-06-29 Schering Corporation Pharmaceutical formulations
WO2009040847A2 (en) * 2007-08-13 2009-04-02 N.B.S. S.R.L. Dermocosmetic compositions based on tamarind seed polysaccharide and vegetable extracts

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GUPTA V, PURI R, GUPTA S, JAIN S, RAO GK.: "Tamarind kernel gum: An upcoming natural polysaccharide", SYST REV PHARM, vol. 1, 2010, pages 50 - 4
LANG P. ET AL., MACROMOLECULES, vol. 26, 1993, pages 3992 - 3998
MURRAY R ET AL: "An outbreak of weaver's cough associated with tamarind seed powder", BRITISH JOURNAL OF INDUSTRIAL MEDICINE, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 14, no. 2, 1 April 1957 (1957-04-01), pages 105 - 110, XP009151988, ISSN: 0007-1072 *
See also references of EP2593119A1
TUFFNELL P G ET AL: "An investigation into the acute respiratory reaction to the inhalation of tamarind seed preparations", BRITISH JOURNAL OF INDUSTRIAL MEDICINE, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 14, no. 4, 1 October 1957 (1957-10-01), pages 250 - 252, XP009151989, ISSN: 0007-1072 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013023856A1 (en) * 2011-08-12 2013-02-21 Zambon S.P.A. Use of a polysaccharide polymer from the seeds of the tamarind seed in protecting against tobacco-associated damages
EA024938B1 (en) * 2011-08-12 2016-11-30 Замбон С.П.А. Use of a polysaccharide polymer from the seeds of the tamarind seed in protecting against tobacco-associated damages

Also Published As

Publication number Publication date
RS54637B1 (en) 2016-08-31
CO6561774A2 (en) 2012-11-15
PT2593119E (en) 2016-03-01
MX2012005818A (en) 2012-09-07
SI2593119T1 (en) 2016-04-29
CN102686232A (en) 2012-09-19
EA201270563A1 (en) 2012-12-28
EA023654B1 (en) 2016-06-30
BR112012011818A2 (en) 2017-09-26
HUE028534T2 (en) 2016-12-28
CN102686232B (en) 2014-12-24
PL2593119T3 (en) 2016-06-30
MY162322A (en) 2017-05-31
ES2560954T3 (en) 2016-02-23
EP2593119A1 (en) 2013-05-22
EP2593119B1 (en) 2015-11-04
BR112012011818B1 (en) 2020-11-24

Similar Documents

Publication Publication Date Title
EP1824450B1 (en) Compositions for intranasal administration
US6899903B2 (en) Composition for cleansing the sinuses
CN107789556A (en) A kind of Juhong Tanke Neulized inhalation pharmaceutical solutions and preparation method thereof
EP2593119B1 (en) Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough
JP2003535130A (en) Control of snoring by oral administration of dimethyl sulfone.
US20080131454A1 (en) Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan
CN108472375A (en) The therapy of middle severe influenza
EP3442583B1 (en) Composition comprising nicotine for treating bleeding of the nasal or paranasal mucosa
CA2701388C (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
EP2741754B1 (en) Use of a polysaccharide polymer from the seeds of the tamarind tree in protecting against tobacco-associated damages
CN111467426B (en) Traditional Chinese medicine patch for moistening lung to arrest cough and preparation method thereof
JP2002030000A (en) Fundamental treatment for common cold
CN109908131A (en) Pharmaceutical composition of nasal irrigation and its preparation method and application
CN1277551C (en) Mint oil preparation for treating obstructive sleep apnea and low ventilation syndrome
JP2003342186A (en) Oral liquid formulation composition for rhinitis
CN107773588A (en) A kind of trollflower Neulized inhalation pharmaceutical solutions and preparation method thereof
DER et al. TREATING DRY COUGH
CN103893158A (en) Application of xylitol in diseases of respiratory system caused by haze
WO2023203306A1 (en) Compositions and applications thereof
Siefkin The management of asthma in family practice
Anatol'evna TA Grechukha, MG Galitskaya
CN107773688A (en) A kind of infantile lung clearing phlegm transforming Neulized inhalation pharmaceutical solutions and preparation method thereof
US20140194515A1 (en) Use of a Composition Comprising an Antacid, a Mucolytic and a Gelling Agent in the Treatment of Cold
UA47593U (en) Syrup for treating and preventing diseases of respiratory tract
CN101831799A (en) Sarcandra glabra essential oil plasticizer for cigarettes and preparation method thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180004954.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11745921

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011745921

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201270563

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/005818

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12106368

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012011818

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2016/0055

Country of ref document: RS

ENP Entry into the national phase

Ref document number: 112012011818

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120517